Myocholine (Bethanechol Chloride)

Bethanechol chloride directly activates muscarinic M3 receptors on smooth‑muscle cells of the urinary and gastrointestinal systems. This activation raises intracellular calcium levels, causing the detrusor muscle of the bladder and intestinal smooth muscle to contract, which facilitates bladder emptying and promotes intestinal motility.

The appropriate dose of Myocholine is determined by the prescribing healthcare professional based on the patient’s condition, age, renal and hepatic function, and response to therapy. Dosage adjustments may be needed for elderly patients or those with organ impairment.

Myocholine is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus, but there are no adequate well‑controlled studies in pregnant women. It should be used during pregnancy only if clearly needed. Limited data are available for breastfeeding; a risk‑benefit assessment should be performed by the prescriber.

To order Myocholine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Myocholine (bethanechol) is a direct muscarinic agonist, whereas alternative agents such as anticholinergics or alpha‑blockers work by different mechanisms. Bethanechol specifically stimulates bladder muscle contraction, offering a targeted approach for patients with functional retention, while other drugs may relieve obstruction or reduce sphincter tone. Choice of therapy depends on the underlying cause and patient tolerance.

Myocholine tablets should be stored at room temperature, below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in areas with high humidity or extreme temperatures, and keep out of reach of children.

Myocholine is taken orally as a tablet. The patient should swallow the tablet whole with a glass of water, preferably on an empty stomach unless otherwise directed by the prescriber. The exact timing and frequency are determined by the healthcare professional based on the individual treatment plan.

Serious risks include bronchospasm, especially in patients with asthma or COPD, severe hypotension, bradycardia, cardiac arrhythmias, and rare allergic reactions such as anaphylaxis. Patients should be monitored for respiratory distress, marked drops in blood pressure, or any signs of an allergic response, and treatment should be discontinued if these occur.

Myocholine is contraindicated in patients with mechanical urinary obstruction, severe asthma or COPD, uncontrolled hypotension, known hypersensitivity to bethanechol or any formulation components, and in individuals taking potent anticholinergic drugs that would negate its effect. Caution is also advised for patients with significant renal or hepatic impairment.